SIOX | Sio Gene Therapies Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4150 - 0.4150
52 Week Range	0.4150 - 0.4150
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	73,975,200
Market Cap	30,699,708
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-06-11

Valuation
Profitability
Growth
Health
P/E Ratio	-1.06
Forward P/E Ratio	N/A
EPS	-0.39
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	12
Country	USA
Website	SIOX

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

SIOX's peers: ABIO, IKT, IMRN, VINC, XOMA, GDTC

*Chart delayed

Analyzing fundamentals for SIOX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see SIOX Fundamentals page.

Watching at SIOX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SIOX Technicals page.